Skip to main content
OpenTrials
Completed

NCT Number: NCT02435693

Pharmaceutical Care Program for Type 2 Diabetes Mellitus

Evaluation of Pharmaceutical Care Program for Type 2 diabetes mellitus in Dhule

Objectives:-

1. To evaluate Pharmaceutical care program in Type2 diabetics. 2. To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus. 3. To study the prevalence of Type2 diabetics cases in Dhule. 4. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics. 5. To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus. 6. To study the impacts of Pharmaceutical care program on glycemic control in patients with Type-2 Diabetes Mellitus. 7. To study the Drug utilization pattern in Type-2 Diabetes Mellitus in civil hospital Dhule. 8. To compare the efficiency of Pharmaceutical care program and drug in patients with Type-2 Diabetes Mellitus. 9. To study the Pharmaco-economic evaluation in Type-2 Diabetes Mellitus patient's. 10. To increase the patient compliance and positive attitude of patients towards the diabetes disease by counseling.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

35 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Tabrej Aj Mujawar

Dhule, Maharashtra, 424001, India

About this study

To evaluate the impacts of Pharmaceutical care on quality of life (QOL) in patient with Type-2 Diabetes Mellitus.

To study the prevalence of Type2 diabetics cases in Dhule. To study the Assessment of different type of adverse drug reactions (ADRs). In Type2 diabetics.

To evaluate the Drug Drug intereaction in Type-2 Diabetes Mellitus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion Criteria:

  • Patients with type 2 diabetes mellitus of either
  • Patients with HbA1c more than 7% and
  • Patients with blood sugar level more than 140 mg / dl

Exclusion criteria

  • Patient with end stage kidney disease.
  • Patient with heart failure.
  • Patient with chronic Diabetes problem and orthopedic problem

Treatment and study plan

PHARMACEUTICAL CARE programe

Other

The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Without PHARMACEUTICAL CARE programe

Other

Primary outcomes

  1. Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded: Fasting blood glucose measurements recorded (mg/dl).Postprandial bloodglucoseRecorded

    Time frame: 24 weeks

    Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded Fasting blood glucose measurements recorded (mg/dl).Postprandial blood glucose Recorded fasting blood glucose

Secondary outcomes

  1. Quality of Life score

    Time frame: 24 weeks

    Quality of Life score

Sponsors and collaborators

Lead sponsor

TABREJ MUJAWAR

Other

Registry information

Official study title

Evaluation of Pharmaceutical Care Program for Type 2 Diabetes Mellitus in Dhule

Acronym: pcp

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
May 6, 2015
Registry last updated
Nov 4, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.